GVM±R in Patients With Relapsed or Refractory Aggressive NHL.

Summary

This is a prospective clinical study to evaluate the safety and efficacy of GVM±R in patients with relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL).

Conditions

• Peripheral T Cell Lymphoma
• Diffuse Large B-cell Lymphoma

Interventions

DRUG

GVM±R regimen

Mitoxantrone hydrochloride liposome (18 mg/m\^2) on day 1； Gemcitabine (800 mg/m\^2) on day 1,8； Vinorelbine (20mg/m\^2) on day 1,8； Rituximab (375mg/m\^2) on day 1; The regimen will be administered every 3 weeks, for a maximum of 6 cycles. The choice of CD20 monoclonal antibody will be determined by the attending physician.

Sponsors & Collaborators

• First Hospital of China Medical University

  collaborator OTHER

• Hebei Medical University Fourth Hospital

  collaborator OTHER

• Chengdu Shangjin Nanfu Hospital

  collaborator UNKNOWN

• Affiliated Cancer Hospital & Institute of Guangzhou Medical University

  collaborator OTHER

• Xuanwu Hospital, Beijing

  collaborator OTHER

• The Affiliated Ganzhou Hospital of Nanchang University

  collaborator OTHER

• Beijing Tongren Hospital

  collaborator OTHER

• The First Affiliated Hospital of Dalian Medical University

  collaborator OTHER

• The First Hospital of Jilin University

  collaborator OTHER

• People's Hospital of Zhengzhou University

  collaborator OTHER

• The First Affiliated Hospital of Bengbu Medical University

  collaborator OTHER

• The Second Affiliated Hospital of Kunming Medical University

  collaborator OTHER

• The First Affiliated Hospital of Nanchang University

  collaborator OTHER

• The Second Affiliated Hospital of Harbin Medical University

  collaborator OTHER

• Shengjing Hospital

  collaborator OTHER

• Peking University Third Hospital

  collaborator OTHER

• First Affiliated Hospital of Harbin Medical University

  collaborator OTHER

• China-Japan Friendship Hospital

  collaborator OTHER

• Institute of Hematology & Blood Diseases Hospital, China

  lead OTHER

Principal Investigators

• Wei Liu · Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC

• Xiaojing Yan · First Hospital of China Medical University

• HaiSheng、Chen Liu 、Huang · Hebei Medical University Fourth Hospital

• Yongqian Jia · Chengdu Shangjin Nanfu Hospital

• Yunhong Huang · Affiliated Cancer Hospital & Institute of Guizhou Medical University

• Xiaobo Wang · The Second Affiliated Hospital of Dalian Medical University

• Wanling Sun · Xuanwu Hospital, Beijing

• Mingxing Zhong · The Affiliated Ganzhou Hospital of Nanchang University

• Liang Wang · Beijing Tongren Hospital

• Xiuli Sun · The First Affiliated Hospital of Dalian Medical University

• Ou Bai · The First Hospital of Jilin University

• Shuxia Guo · People's Hospital of Zhengzhou University

• Yanli Yang · The First Affiliated Hospital of Bengbu Medical University

• Zeping Zhou · The Second Affiliated Hospital of Kunming Medical University

• Fei Li · The First Affiliated Hospital of Nanchang University

• Aichun Liu · The Second Affiliated Hospital of Harbin Medical University

• Aijun Liao · Shengjing Hospital

• Hongmei Jing · Peking University Third Hospital

• Shuye Wang · First Affiliated Hospital of Harbin Medical University

• Zhenling Li · China-Japan Friendship Hospital

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Max Age

65 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2024-01-17

Primary Completion

2025-12-30

Completion

2027-12-30

Countries

• China

Study Locations